USP13 and cholangiocarcinoma: Recently, it has been reported that USP13 is co-overexpressed with c-Myc in many tumors, such as NSCLC (Wu et al., 2019), cholangiocarcinoma (CAA) (Zhou et al., 2020), GSCs (Fang et al., 2017), and hepatocellular carcinoma (HCC) (Huang et al., 2020).